Genome-wide association results are being widely heralded [2] as a confirmation that many of the precepts (and promises) of 'big science' projects like the human genome and HapMap projects are being realized. After so many years of frustration and disagreement in the field, the sudden appearance of both real discoveries and real standards is most welcome. Henceforth, claims that variation in a particular gene contributes to disease susceptibility must demonstrate significance taking into account all the hypotheses that have been evaluated, and must be replicated using the same SNP and the same phenotype [3] . Understandably, these standards may percolate with different speeds through the different research communities that face specific practical challenges. Naysayers may challenge the efficacy and necessity of the HapMap project as a means to this end [4] , but few practitioners will doubt its value and utility. Nevertheless, without wishing to diminish from the scale of these achievements or the transition represented by genome-wide association, it is worth returning to what the real motivation is for genetic studies, and judging progress by that metric.
There are three fundamental reasons to want to map gene variants for common disease. These are: first, to predict risk and therefore allow tailoring of lifestyle choices to risk; second, to improve understanding of disease pathophysiology in a manner that suggests new directions for therapy; and third, to identify subclasses of clinically similar diseases that nevertheless have different genetic etiologies and hence should respond to different therapies.
By the standards of these fundamental goals whole genome studies of common diseases have yet to prove themselves. Quite aside from practical challenges in relation to regulatory oversight and implementation of robust genetic counseling protocols, genome-wide association data are currently explanatory but are not yet usefully predictive. Even in the most successful case, Crohn's Disease, with nine validated associations, most of the genetic risk in the population remains to be explained, and the proportional contribution of parSNPs to family clustering seems to be less than a few percent [1, 5] . If there are other factors out there, they are unlikely to individually account for more than one or two percent of susceptibility, and hence some would argue that they will be practically and clinically irrelevant. By contrast, it has been suggested that pharmacogenetics is likely to provide more immediate clinical returns than disease genetics, a good example of which is the recent demonstration that HLA-B genotype predicts hypersensitive response to the anti HIV drug abacavir [6] .
The term parSNP serves as a reminder that the purpose of genome-wide association is not so much to find individual risk alleles as population attributable risk factors. Like the concept of heritability, which applies to populations not individuals, parSNPs are identified by their influence averaged across individuals within a population. We are not aware of any claims that common disease variants would typically be prognostic, and suspect that geneticists much more commonly imagine that there are likely dozens if not hundreds of variants that can contribute to any given disease. Individuals who happen to inherit an excess of these, and experience damning environmental circumstances, are more susceptible than others. It is the constellation of factors that is potentially predictive, not single variants.
There are some tantalizing suggestions from multivariate modeling that this may be the case. As a class, SNPs in genes involved in steroid hormonal regulation and cell cycle control are more commonly associated with breast cancer than if you query similarly sized sets of SNPs in randomly chosen loci [7] . Similarly, a recent reanalysis of a low resolution genome-wide association for Parkinson's disease, which initially came up with a single strong candidate parSNP, implicates genes involved in axonal guidance as a class in the etiology of this neurodegenerative disease [8] . The joint probability of association of a signature involving 117 genes with Parkinson's disease is in the range of 10
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. André Rzhetsky and colleagues [9] arrived at a similar conclusion without even looking at genotypes. They scoured the medical records of 1.5 million patients of the Columbia University Medical System and considered the overlap in disease diagnoses for 124 relatively common diseases. After adjusting for correlations due to age and sex, they find striking tendencies for certain diseases to co-occur in individuals (for example, autism, bipolar depression and schizophrenia). They even estimate that some of these diseases are likely to share as many as 20% or more of their susceptibility alleles.
We are led to conclude that genome-wide association is more likely to have an impact with respect to the second and third objectives presented above. For example, a genome-wide association for asthma supports increased interest in airway remodeling alongside inflammatory hyper-responsiveness [10] ; autophagy is implicated in the etiology of inflammatory bowel disease [5] ; and the bipolar disorder data [1] place the copious literature pertaining to neurotransmitters and synaptic transmission as mediators of depression in a genome-wide perspective. The impact of genetics on disease sub-classification is yet to be felt, but clearly there is now good reason to expect advances.
A remarkable but yet-to-be remarked upon aspect of the recent deluge of genome-wide association data is the apparent diversity in the yield of associations for different diseases. Why, for example, is it that hypertension and bipolar disorder are devoid of the class of highly significant hits that characterize the immune-related diseases Crohn's disease and type 1 diabetes? A common view is that this as essentially the luck of the draw -some traits happen to have polymorphisms influencing them that are both common and important enough to be detectable in manageable sample sizes, and other traits do not. A more intriguing interpretation is that the data are telling us that some traits are largely resistant to the effects of common genetic variation whereas others are much more susceptible.
While it is perhaps too early to declare a clear pattern, we suspect there may be evolutionary explanations for the differences amongst traits. Contrast, for example, two quantitative traits: blood pressure and HIV viral load following infection. While hypertension produced no clear discoveries in 2000 cases [1] , a study of just 500 subjects characterized for HIV-1 viral load identified three variants explaining 14% of the total variation [11] . We doubt these differences are the luck of the evolutionary draw and suspect they may result from a kind of evolutionary canalization. A key difference between HIV-1 set point and blood pressure is that blood pressure is likely to have been close to a long-term optimum, whereas this is not the case for the HIV-1 setpoint.
Canalization refers to the observation that genetic systems have often evolved robustness to genetic and environmental perturbation [12] . Expression of phenotypic variation is suppressed by the network of epistatic interactions among alleles within the normal environmental context that an organism finds itself in. Take the organism outside of this buffering zone, for example, by dramatically changing diet and immune exposure, and cryptic variation can be exposed [13] . Variants that under 'normal' circumstances would not contribute appreciably to disease do so in the modern world because they push individuals closer to the threshold upon which the new environment acts ( Figure 1A) .
The possibility that (de)canalization helps to explain the heterogeneity of genome-wide association results to date should be considered. A tentative indication that genetic buffering may suppress the effects of mutations that would otherwise lead to disease is seen in the shape of the Q-Q plots from the Wellcome Trust Case Control Consortium study [1] (Figure 1B,C) . These plots show the relationship between observed and expected test statistics, and for five of the diseases, the observed curves deviate sharply to higher than expected test statistic values at the upper extreme, due to the parSNPs. For bipolar disorder and hypertension, by contrast, these curves actually plateau off as would be observed if the effects of candidate parSNPs were buffered.
Intriguingly, there is also a difference in the polarity of associations for different classes of disease. Most of the parSNPs are more likely tagging SNPs than the causal sites, so it is not clear what their relationships to the ancestral status of the true disease-promoting variants are. Nevertheless, including moderate evidence for association, almost two thirds of all risk-associated SNPs in the Wellcome Trust Case Control Consortium study [1] are ancestral, implying that the derived allele in the human lineage is offering protection from disease. More strikingly, for hypertension, all of the (moderate) risk alleles are ancestral, and for rheumatoid arthritis 10 of 12 are. The clear exception is Crohn's disease, for which 10 of 16 of the risk-associated parSNPs that we were able to polarize unambiguously are derived.
A prediction of the decanalization hypothesis is that as the prevalence of a disease increases in modern society, the likelihood of genome-wide association uncovering susceptibility alleles also increases. Inflammatory diseases have increased in prevalence recently, arguing that deleterious interactions between the modern environment and derived alleles corrode the evolved buffering, which in turn may expose ancestral alleles to disease promotion. Our recent demonstration of highly significant associations of derived alleles with HIV setpoint [11] may be another instance of this phenomenon. Not having been exposed to the virus until a few generations ago, there has been no time for the genome to evolve canalization, and additive variation for viral titers segregates in human populations.
This hypothesis puts us slightly at odds with the recommendations of Merikangas and Risch [14] in relation to public health priorities for investment in genomic research. They argued that there is little point in expenditure on genome-wide association for diseases where the genetic contribution pales in comparison to environmental factors, since public health campaigns to modify behavior or otherwise address the environmental risk will be far more effective than treatments that target genetic variation. However, strong environmental perturbations are precisely the conditions under which hidden genetic variants may be revealed and hence under which genome-wide association may be most likely to succeed. The immediate benefit of parSNPs is not as biomarkers for personalized medicine, but rather as entry points into the hidden genetic text of complex disease. A policy consequence is that genetic advances may, counterintuitively, be most obvious where humans are exposed to novel environmental exposures, including nutrition and childhood infection. Findings in at risk populations are likely to carry over into canalized ones, and the key is to seek understanding of all facets of risk. (A) Model of effect of canalization on disease. Each genotype in a population is associated with a level of disease susceptibility that will typically be normally distributed but with a liability threshold indicated by the vertical broken line. Under normal environmental or genetic circumstances (green), very few individuals are above the threshold, but in an altered environment or non-equilibrium genetic circumstances (red), the variance of the susceptibility increases, and more genotypes give rise to individuals above the threshold, exposing hidden variation. (B) For coronary artery disease, Crohn's disease, types 1 and 2 diabetes, and rheumatoid arthritis, the observed association test statistics (negative log p-values) exceed the expected range of values shown in light green. (C) For bipolar disorder and hypertension, by contrast, high association scores are not seen and the Q-Q plot curve actually flattens off to a plateau, possibly suggesting buffering.
